Dr. Soliman Abdel Kader Fakeeh Stocks

SAR 36.46Last Updated 27.04.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

SAR 2.24B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SAR 36.46
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Dr. Soliman Abdel Kader Fakeeh Hospital Company establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. It offers various services, such as assisted reproductive therapy, audiology, bariatric surgery, breast feeding clinic, cardiac surgery, cardiology, chest and respiratory diseases, chiropractic medicine, dental and maxillofacial, dermatology, otorhinolaryngology, endocrinology, ophthalmology, family medicine, gastroenterology, general surgery, geriatric medicine, hematology, hyperbaric oxygen service, infectious diseases, internal medicine, interventional radiology, psychiatry, nephrology, neuro surgery, neurology, nutrition, obstetrics and gynecology, oncology, orthopedics, pain treatment service, palliative care services, pediatric department, pediatric surgery, physical medicine and rehabilitation, plastic surgery, rheumatology, sleep disorders clinic, speech therapy, thoracic surgery, urology, and vascular surgery. The company also operates AIRS, NICU, endoscopy, the institute of robotic surgery, anesthesia, emergency medicine, intensive care, renal dialysis, rhinoplasty center, and burn units; establishes and manages pharmacies; and laboratory services. In addition, it engages in the wholesale and retail of medical equipment; and maintenance of IT equipment and software related services. The company was founded in 1978 and is headquartered in Jeddah, the Kingdom of Saudi Arabia.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 4017.SR is 42 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks